يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva"', وقت الاستعلام: 1.64s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Fissolo N, Matute-Blanch C, Costa C, Pinteac R, Brito V, Comabella Lopez M Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Osman M Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark. Miró B Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Sanchez A Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Genetics, Microbiology and Statistics Department, Universitat de Barcelona, Spain. Montalban X Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Center for Multiple Sclerosis, St. Michael’s Hospital, University of Toronto, ON, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Neurology neuroimmunology & neuroinflammation.;8(2); https://doi.org/10.1212/NXI.0000000000000941Test; info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0015%2F0004; Fissolo N, Matute-Blanch C, Osman M, Costa C, Pinteac R, Miró B, et al. CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021 Mar;8(2):e941.; https://hdl.handle.net/11351/7703Test; 000656639200009

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Comabella M, Sastre-Garriga J, Pinteac R, Fissolo N, Vidal-Jordana A, Montalban X Unitat de Neuroimmunologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Borras E Proteomics Unit, Universitat Pompeu Fabra, Barcelona. Villar LM Departments of Neurology and Immunology, Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid. Saiz A Service of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi Sunyer, University of Barcelona. Martínez-Yélamos S Department of Neurology, Bellvitge University Hospital, Barcelona, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Neurology - Neuroimmunology & Neuroinflammation;8(6); https://doi.org/10.1212/NXI.0000000000001082Test; Comabella M, Sastre-Garriga J, Borras E, Villar LM, Saiz A, Martínez-Yélamos S, et al. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Nov;8(6):e1082.; https://hdl.handle.net/11351/7442Test; 000712132000035

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Zackowski KM National MS Society, New York, NY, USA. Freeman J School of Health Professions, University of Plymouth, Plymouth U. Brichetto G Research in Rehabilitation, Italian MS Society and Foundation, Milan, Italy. Centonze D Department of Medicine, University of Rome Tor Vergata, Rome, Italy. Dalgas U Department of Public Health, Aarhus University, Aarhus, Denmark. DeLuca J Department of Research, Kessler Foundation, West Orange, NJ, USA. Sastre-Garriga J Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Multiple Sclerosis Journal;27(7); https://doi.org/10.1177/1352458521999970Test; Zackowski KM, Freeman J, Brichetto G, Centonze D, Dalgas U, DeLuca J, et al. Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. Mult Scler. 2021 Jun;27(7):989–1001.; https://hdl.handle.net/11351/7748Test; 000652834300003

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Pérez-Miralles FC Neuroimmunology Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Prefasi D Department of Medical, Roche Farma S.A, Madrid, Spain. García-Merino A Department of Neurology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. Ara JR Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain. Izquierdo G Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain. Meca-Lallana V Department of Neurology, Hospital Universitario La Princesa, Madrid, Spain. Ramió-Torrentà L Unitat de Neuroimmunologia i Esclerosi Múltiple, Departament de Neurologia, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Institut d’Assistència Sanitària, Salt, Spain. Institut d’Investigació Biomèdica de Girona (IDIBGI), Salt, Spain. Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain, Hospital Universitari de Girona Dr Josep Trueta

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Brain and Behavior;11(4); https://doi.org/10.1002/brb3.2044Test; Pérez-Miralles FC, Prefasi D, García-Merino A, Ara JR, Izquierdo G, Meca-Lallana V, et al. Brain Behav. 2021 Apr;11(4):e02044.; https://hdl.handle.net/11351/6632Test

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Montalban X Hospital Universitari Vall d’Hebron, Barcelona, Spain. Hauser SL University of California, San Francisco, United States. Kappos L University Hospital Basel, Basel, Switzerland. Arnold DL, Bar-Or A McGill University, Montreal, Canada. Comi G University Vita-Salute San Raffaele, Milan, Italy., Hospital Universitari Vall d'Hebron

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: New England Journal of Medicine;376(3); Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–220.; http://hdl.handle.net/11351/3845Test; WOS:000392199100005

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Zackowski KM National MS Society, New York, NY, USA. Freeman J School of Health Professions, University of Plymouth, Plymouth U. Brichetto G Research in Rehabilitation, Italian MS Society and Foundation, Milan, Italy. Centonze D Department of Medicine, University of Rome Tor Vergata, Rome, Italy. Dalgas U Department of Public Health, Aarhus University, Aarhus, Denmark. DeLuca J Department of Research, Kessler Foundation, West Orange, NJ, USA. Sastre-Garriga J Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Zackowski KM National MS Society, New York, NY, USA. Freeman J School of Health Professions, University of Plymouth, Plymouth U. Brichetto G Research in Rehabilitation, Italian MS Society and Foundation, Milan, Italy. Centonze D Department of Medicine, University of Rome Tor Vergata, Rome, Italy. Dalgas U Department of Public Health, Aarhus University, Aarhus, Denmark. DeLuca J Department of Research, Kessler Foundation, West Orange, NJ, USA. Sastre-Garriga J Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia